Culture
In surprise move, FDA rejects cancer drug expected to rival The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.
The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.
Dr. Kai NakamuraChief Science CorrespondentPublished Aug 10, 2026 at 11:45 AM EDT · 1 min read
In surprise move, FDA rejects cancer drug expected to rival The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis. The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.